Rhumbline Advisers grew its stake in Cara Therapeutics Inc (NASDAQ:CARA) by 56.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 44,072 shares of the biopharmaceutical company’s stock after buying an additional 15,984 shares during the quarter. Rhumbline Advisers owned 0.11% of Cara Therapeutics worth $573,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Cara Therapeutics by 36.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,601 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 964 shares during the last quarter. Avondale Wealth Management lifted its stake in Cara Therapeutics by 50.0% during the fourth quarter. Avondale Wealth Management now owns 3,000 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 1,000 shares during the last quarter. Legal & General Group Plc lifted its stake in Cara Therapeutics by 36.2% during the third quarter. Legal & General Group Plc now owns 5,538 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 1,472 shares during the last quarter. American International Group Inc. lifted its stake in Cara Therapeutics by 22.4% during the third quarter. American International Group Inc. now owns 21,610 shares of the biopharmaceutical company’s stock worth $518,000 after purchasing an additional 3,949 shares during the last quarter. Finally, Morgan Stanley lifted its stake in Cara Therapeutics by 6.3% during the third quarter. Morgan Stanley now owns 81,338 shares of the biopharmaceutical company’s stock worth $1,948,000 after purchasing an additional 4,840 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

Several research firms recently weighed in on CARA. Zacks Investment Research cut Cara Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. BidaskClub upgraded Cara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, March 12th. Jefferies Financial Group began coverage on Cara Therapeutics in a research note on Wednesday, February 6th. They set a “buy” rating and a $22.00 target price for the company. Bank of America began coverage on Cara Therapeutics in a research note on Tuesday, January 15th. They set a “neutral” rating and a $19.00 target price for the company. Finally, HC Wainwright set a $30.00 target price on Cara Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 20th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $24.03.

CARA opened at $19.46 on Tuesday. The company has a market cap of $748.87 million, a price-to-earnings ratio of -9.45 and a beta of 2.68. Cara Therapeutics Inc has a 52 week low of $11.46 and a 52 week high of $24.30.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.07. The firm had revenue of $5.53 million for the quarter, compared to analyst estimates of $3.35 million. Equities analysts expect that Cara Therapeutics Inc will post -2.35 EPS for the current year.

In other news, insider Frederique Ph.D. Menzaghi sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $18.65, for a total value of $373,000.00. Following the transaction, the insider now owns 139,582 shares of the company’s stock, valued at $2,603,204.30. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Scott Terrillion sold 3,100 shares of the business’s stock in a transaction that occurred on Friday, December 28th. The shares were sold at an average price of $12.51, for a total value of $38,781.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 144,983 shares of company stock worth $2,178,154. 6.70% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Rhumbline Advisers Buys 15,984 Shares of Cara Therapeutics Inc (CARA)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2019/03/19/rhumbline-advisers-buys-15984-shares-of-cara-therapeutics-inc-cara.html.

About Cara Therapeutics

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Further Reading: What are the risks of holding treasury bonds?

Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.